Last reviewed · How we verify

3APS — Competitive Intelligence Brief

3APS (3APS) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: P2X3 receptor antagonist. Area: Respiratory.

phase 3 P2X3 receptor antagonist P2X3 Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

3APS (3APS) — Bellus Health Inc. - a GSK company. 3APS is a selective P2X3 receptor antagonist that blocks pain signaling in sensory neurons to reduce chronic cough.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
3APS TARGET 3APS Bellus Health Inc. - a GSK company phase 3 P2X3 receptor antagonist P2X3
RTX-GRT7039 RTX-GRT7039 Grünenthal GmbH phase 3 P2X3 receptor antagonist P2X3
MR308 MR308 Mundipharma Research GmbH & Co KG phase 3 P2X3 receptor antagonist P2X3
BLU-5937 BLU-5937 Bellus Health Inc. - a GSK company phase 3 P2X3 receptor antagonist P2X3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (P2X3 receptor antagonist class)

  1. Bellus Health Inc. - a GSK company · 2 drugs in this class
  2. Grünenthal GmbH · 2 drugs in this class
  3. Mundipharma Research GmbH & Co KG · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). 3APS — Competitive Intelligence Brief. https://druglandscape.com/ci/3aps. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: